With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
Another positive finding in triple-negative breast cancer.
June 13, 2017. The results of the FinXX trial were published last week in JAMA Onc showing improvement in recurrence-free survival (RFS) among triple-negative breast cabcer (TNBC) patients randomized to receive Xeloda (X) as a component of adjuvant chemotherapy. 1500 patients with T2 or node+ invasive breast cancer were randomized to adjuvant Taxotere (T) x 3 -> ECF x 3 versus TX -> ECF x 3 with a primary endpoint of RFS. While there were no significant differences between the two treatment cohorts, a pre-planned subgroup analysis of 202 TNBC patients showed a significant advantage of adding Xeloda in terms of RFS (HR 0.53) and OS (HR 0.55). This bolsters results of the recently published Create-X trial and means Xeloda is getting ready for its debut leading role outside the GI cancer genre.